WHO SOLIDARITY in full.
No significant improvement in survival with hydroxychloroquine, lopinavir, interferon, or remdesevir in hospitalised patients.
Negative results are important - allow us all to refocus drug development and health resources.
nejm.org/doi/full/10.10…
No significant improvement in survival with hydroxychloroquine, lopinavir, interferon, or remdesevir in hospitalised patients.
Negative results are important - allow us all to refocus drug development and health resources.
nejm.org/doi/full/10.10…
Consistent in subgroups: 
Meta-analysis of remdesevir:
- no clear benefit overall
- to the optimist there may be an unproven modest benefit in those with milder disease, but the absolute benefit would be very small, number of patients huge, and cost enormous
- no clear benefit overall
- to the optimist there may be an unproven modest benefit in those with milder disease, but the absolute benefit would be very small, number of patients huge, and cost enormous
Enormous credit to @WHO for organising this very large, randomised trial assessing effects on mortality.
An impressive & elegant study producing results that can reliably inform individual patient care, public health policy, and future drug development.
Thanks to all involved.
An impressive & elegant study producing results that can reliably inform individual patient care, public health policy, and future drug development.
Thanks to all involved.
• • •
Missing some Tweet in this thread? You can try to
force a refresh
